American Injectables, a United States-based manufacturer of sterile injectable parenteral drugs, announced on Monday that it has completed the commissioning and qualification of its newly constructed facility in Tampa, and also completed a Series A financing.

This move is intended to help fill the gap in the United States-based manufacturing of sterile injectables to improve present drug shortages.

The company has completed USD19m Series A fundraising, led by New Rhein, that is intended to help it to increase manufacturing capabilities, fund R&D and launch its first product. R&D investment is intended to increase the range of both generic and branded hospital products.

CEO Adam Levitt, said, 'We are excited to start registration batches for FDA submission in the coming months and preparing for our first FDA inspection and approval. I am further announcing the addition of Dr Vijay Nekkanti, VP R&D to the leadership team. Dr Nekkanti most recently was leading R&D for Humanwell and has held leadership roles with Custopharm, and Dr. Reddy's Lab and Pfizer. I am very excited about this new critical hire. American Injectables, Inc is now well-positioned with Integrated Product Development and Manufacturing engine that quickly and flexibly brings new products to market. With the addition of Dr Nekkanti we have completed building a world class leadership team.'